- Home
- EMBC
EMBC
Embecta Corp.
as 12-17-2024 4:00pm EST
Embecta Corp is a medical technology company. The company develops innovative technology, services, and solutions that help advance both clinical therapy for patients and clinical processes for healthcare providers. Its products include BD Pyxis, PureWick, Phasix among others.
| Founded: | 1924 | Country: | United States |
| Employees: | N/A | City: | WILMINGTON |
| Market Cap: | 753.0M | IPO Year: | N/A |
| Target Price: | $19.00 | AVG Volume (30 days): | 491.4K |
| Analyst Decision: | Buy | Number of Analysts: | 2 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 1.34 | EPS Growth: | 9.84 |
| 52 Week Low/High: | $9.93 - $21.48 | Next Earning Date: | 02-07-2025 |
| Revenue: | $1,123,100,000 | Revenue Growth: | 0.21% |
| Revenue Growth (this year): | 1.77% | Revenue Growth (next year): | 1.14% |
Latest Embecta Corp. News
EMBC Breaking Stock News: Dive into EMBC Ticker-Specific Updates for Smart Investing
Argus Research
8 days ago
EMBC: What does Argus have to say about EMBC?
Zacks
9 days ago
Here Is Why Bargain Hunters Would Love Fast-paced Mover Embecta Corp. (EMBC)
MedTech Dive
12 days ago
Embecta to cut 125 jobs after ending insulin patch pump
Argus Research
15 days ago
EMBC: Raising target price to $16.00
Zacks
16 days ago
Best Value Stocks to Buy for December 2nd
Simply Wall St.
19 days ago
Is It Time To Consider Buying Embecta Corp. (NASDAQ:EMBC)?
MT Newswires
21 days ago
BTIG Research Upgrades Embecta to Buy From Neutral, $26 Price Target
TipRanks
21 days ago
Embecta to discontinue insulin patch pump program, initiates restructuring plan
Compare EMBC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "EMBC Embecta Corp. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.